Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Mantle-Cell 6Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, B-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Lymphoma 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 53Vincristine 33blinatumomab 30Prednisone 28Methotrexate 28Cytarabine 26Dexamethasone 24Specimen Handling 21Rituximab 21Doxorubicin 20merphos 19Mercaptopurine 19Etoposide 18prednylidene 17fludarabine 17deltacortene 17Calcium Dobesilate 17Biopsy 17dexamethasone acetate 16dexamethasone 21-phosphate 16auricularum 16N,N-dicyclohexyl-isoborneol-10-sulfonamide 16azathiopurine 15Inotuzumab Ozogamicin 15pegaspargase 14venetoclax 13Leucovorin 13CT-P10 13Asparaginase 13Spinal Puncture 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Burkitt Lymphoma × brexucabtagene autoleucel × 1 year × Clear all
NCT06144606 2026-03-31

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05537766 2026-03-10

ZUMA-25

Gilead Sciences

Phase 2 Terminated
19 enrolled 28 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡